Strategic Financial Concepts LLC Invests $41.53 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 176,485 shares of the biopharmaceutical company’s stock, valued at approximately $41,529,000. Strategic Financial Concepts LLC owned about 0.14% of Alnylam Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Bleakley Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 16.9% in the 4th quarter. Bleakley Financial Group LLC now owns 2,590 shares of the biopharmaceutical company’s stock valued at $610,000 after acquiring an additional 375 shares during the period. Choreo LLC grew its stake in shares of Alnylam Pharmaceuticals by 8.6% during the fourth quarter. Choreo LLC now owns 4,748 shares of the biopharmaceutical company’s stock worth $1,121,000 after purchasing an additional 378 shares in the last quarter. E. Ohman J or Asset Management AB raised its position in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. E. Ohman J or Asset Management AB now owns 6,100 shares of the biopharmaceutical company’s stock worth $1,435,000 after acquiring an additional 700 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $61,160,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Alnylam Pharmaceuticals by 7.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 38,997 shares of the biopharmaceutical company’s stock valued at $9,176,000 after acquiring an additional 2,657 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,964 shares of company stock worth $20,622,925 in the last ninety days. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, January 21st. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James boosted their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $278.25 on Friday. The stock’s fifty day moving average is $252.31 and its two-hundred day moving average is $261.81. The stock has a market capitalization of $35.89 billion, a price-to-earnings ratio of -106.20 and a beta of 0.35. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.